Detopoulou Paraskevi, Nomikos Tzortzis, Fragopoulou Elisabeth, Antonopoulou Smaragdi, Kotroyiannis Iason, Vassiliadou Carmen, Panagiotakos Demosthenes B, Chrysohoou Christina, Pitsavos Christos, Stefanadis Christodoulos
Department of Nutrition Science-Dietetics, Harokopio University, 70 E1 Venizelou Street, Athens, 17671, Greece.
Clin Biochem. 2009 Jan;42(1-2):44-9. doi: 10.1016/j.clinbiochem.2008.09.113. Epub 2008 Oct 15.
To evaluate platelet activating factor (PAF) levels, its metabolic enzymes activity and its associations with other inflammatory markers in heart failure (HF) patients.
PAF, and two of its key biosynthetic enzymes [lyso-PAF acetyltransferase (lyso-PAF-AT) and DTT-insensitive CDP-choline:1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase (PAF-CPT)] along with its catabolic enzymes [PAF-acetylhydrolase (PAF-AH) and lipoprotein-associated phospholipase-A(2) (Lp-PLA(2))] were measured in serum and leukocytes of twelve newly diagnosed male HF patients. Serum CRP, TNF-alpha, IL-6, sCD14 and CD40L were also determined.
PAF ranged from 0.03 to 5.6 pmol/mL. Median lyso-PAF-AT, PAF-CPT, PAF-AH and Lp-PLA(2) activities were 4.1, 68.42, 644.44 pmol/min/mg protein and 51.42 pmol/min/microL correspondingly. Lyso-PAF-AT and PAF-CPT activities positively correlated with CRP, IL-6 and with each other, whereas PAF-CPT activity correlated with sCD14 and CD40L (P<0.05).
PAF's biosynthetic enzyme activities correlated with inflammatory and immunologic molecules, which are activated in HF. Our study indicates a potential role of PAF in HF patients.
评估心力衰竭(HF)患者的血小板活化因子(PAF)水平、其代谢酶活性及其与其他炎症标志物的关联。
在12例新诊断的男性HF患者的血清和白细胞中检测PAF及其两种关键生物合成酶[溶血PAF乙酰转移酶(lyso-PAF-AT)和二硫苏糖醇不敏感的CDP-胆碱:1-烷基-2-乙酰基-sn-甘油胆碱磷酸转移酶(PAF-CPT)]以及其分解代谢酶[PAF-乙酰水解酶(PAF-AH)和脂蛋白相关磷脂酶A2(Lp-PLA2)]。还测定了血清CRP、TNF-α、IL-6、可溶性CD14和CD40L。
PAF范围为0.03至5.6 pmol/mL。溶血PAF-AT、PAF-CPT、PAF-AH和Lp-PLA2活性的中位数分别为4.1、68.42、644.44 pmol/min/mg蛋白质和51.42 pmol/min/μL。溶血PAF-AT和PAF-CPT活性与CRP、IL-6呈正相关,且二者之间也呈正相关,而PAF-CPT活性与可溶性CD14和CD40L相关(P<0.05)。
PAF的生物合成酶活性与HF中被激活的炎症和免疫分子相关。我们的研究表明PAF在HF患者中具有潜在作用。